2-Bromomescaline

2-Bromomescaline
Clinical data
Other names	2-BM; 2-Br-M; 2-Bromo-3,4,5-trimethoxyphenethylamine
Drug class	Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Identifiers
	IUPAC name 2-(2-Bromo-3,4,5-trimethoxyphenyl)ethanamine;
CAS Number	37015-19-3 ;
PubChem CID	16637783;
ChemSpider	17574207 ;
UNII	A9M89XG7QW;
CompTox Dashboard (EPA)	DTXSID301032900 ;
Chemical and physical data
Formula	C11H16BrNO3
Molar mass	290.157 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C(=C(C(=C1)CCN)Br)OC)OC;
	InChI InChI=1S/C11H16BrNO3/c1-14-8-6-7(4-5-13)9(12)11(16-3)10(8)15-2/h6H,4-5,13H2,1-3H3; Key:UXQBKANLBLUVMK-UHFFFAOYSA-N;

2-Bromomescaline (2-BM or 2-Br-M), also known as 2-bromo-3,4,5-trimethoxyphenethylamine, is a putative psychedelic drug of the scaline family and derivative of the phenethylamine hallucinogen mescaline which has an unusual 2-bromo substitution. It is an agonist for serotonin receptors, with a binding affinity of 215 nM at 5-HT_1A, 513 nM at 5-HT_2A and 379 nM at 5-HT_2C, so while it is around 10 times more tightly binding than mescaline at 5-HT_1A and 5-HT_2A receptors, it is over 20 times more potent at 5-HT_2C. The drug was 5-fold more potent in substituting for LSD than mescaline in rats. It is not known to have been tested in humans. 2-Bromomescaline was first described in the scientific literature, as a chemical intermediate, in 1972. It has been reported as a designer drug, first identified in Austria in January 2023. The drug is not a controlled substance in Canada as of 2025.